

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

SALE OF EXISTING SHARES BY SUBSTANTIAL SHAREHOLDERS

AND

RESUMPTION OF TRADING

CSPC Pharmaceutical Group Limited (the “**Company**”) makes this announcement in accordance with Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance.

SALE OF SHARES BY SUBSTANTIAL SHAREHOLDERS

The board of directors (the “**Board**”) of the Company has been informed by Jinling Investment Limited (“**Jinling**”) and Joyful Horizon Limited (“**Joyful Horizon**”), each being a substantial shareholder (as defined under the Listing Rules) of the Company, that on 10 October 2013, Jinling and Joyful Horizon entered into an agreement with a third party independent from the Company in relation to the sale of 362,000,000 shares (the “**JIL Sale Shares**”) and 138,000,000 shares (“**JHL Sale Shares**”, together with the JIL Sale Shares, the “**Sale Shares**”), respectively, in the Company at a price of HK\$4.05 each (the “**Sale**”). The Sale Shares represent approximately 13.07% of the total issued share capital of the Company as at the date of this announcement.

Immediately before the completion of the Sale, Jinling and Joyful Horizon are interested in approximately 12.00% and 39.32%, respectively, of the total issued share capital of the Company. Both Jinling and Joyful Horizon are wholly owned subsidiaries of Massive Top Limited (“**MTL**”). Immediately before the completion of the Sale, MTL, through its wholly owned subsidiaries (consisting of Jinling, Joyful Horizon, China Charmaine Pharmaceutical

Company Limited and Massive Giant Group Limited), is interested in approximately 73.23% of the total issued share capital of the Company.

Immediately upon the completion of the Sale, the shareholdings of Jinling and Joyful Horizon will be reduced to approximately 2.53% and 35.71%, respectively, of the total issued share capital of the Company, and the indirect interest of MTL through its wholly owned subsidiaries referred to above in the Company will be reduced to approximately 60.16% of the total issued share capital of the Company.

RESUMPTION OF TRADING

At the request of the Company, trading in the shares of the Company has been halted from 9:00 a.m. on 10 October 2013 pending the release of this announcement. Application will be made by the Company to The Stock Exchange of Hong Kong Limited for the resumption of trading of the shares of the Company from 9:00 a.m. on 11 October 2013.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 10 October 2013

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. HUO Zhenxing, Mr. QI Moujia, Mr. GUO Shichang, Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo and Mr. ZHANG Fawang as independent non-executive directors.